key: cord-0716189-tu7zbyds
authors: Wang, Maofeng; Wu, Cancan; Liu, Nan; Zhang, Fengyu; Dong, Hongjie; Wang, Shuai; Chen, Min; Jiang, Xiaoqiong; Gu, Lichuan
title: SARS-CoV-2 RdRp uses NDPs as a substrate and is able to incorporate NHC into RNA from diphosphate form molnupiravir
date: 2022-04-11
journal: bioRxiv
DOI: 10.1101/2021.11.15.468737
sha: 31ea659abe7319479e6e965d055e1ee65d092550
doc_id: 716189
cord_uid: tu7zbyds

The coronavirus disease 2019 (COVID-19) has been ravaging throughout the world for more than two years and has severely impaired both human health and the economy. The causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) employs the viral RNA-dependent RNA polymerase (RdRp) complex for genome replication and transcription, making RdRp an appealing target for antiviral drug development. Here, we reveal that RdRp can recognize and utilize nucleoside diphosphates (NDPs) as a substrate to synthesize RNAs with an efficiency of about two thirds of using nucleoside triphosphates (NTPs) as a substrate. NDPs incorporation is also template-specific and has high fidelity. Moreover, RdRp can incorporate β-d-N4-hydroxycytidine (NHC) into RNA while using diphosphate form molnupiravir (MDP) as a substrate. We also observed that MDP is a better substrate for RdRp than the triphosphate form molnupiravir (MTP).

The pandemic of coronavirus disease 2019 (COVID-19) has severely impacted human 46 health and the global economy since the outbreak in late 2019 1,2 . The causative agent, 47 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is homologous to 48 2002 SARS-CoV with a genome sequence similarity of 79% 3,4 , forming a sister clade 49 to SARS-CoV and considered a newly β-coronavirus 5 . As of the date of writing, more 50 than 491.75 million infections and more than 6.17 million deaths have been confirmed 51 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports). 52 Although a variety of vaccines have been developed to contain the pandemic, the 53 rapidly spreading mutant strains presses need to develop effective medication or 54 treatment to counter the virus 6-9 . To date, the most promising RdRp inhibitors are nucleotide/nucleoside analogs (NA). 65 NA prodrugs are designed to be metabolized to the active 5'-triphosphate form (5'-TP) 66 4 / 27 once inside cells 19 , thus they can compete with endogenous nucleotides for 67 incorporation into newly synthesized viral RNAs, resulting in viral genomes lethal 68 mutation or inactivation 20 . Remdesivir is a broad antiviral drug approved for the 69 treatment of SARS-CoV-2, which can be incorporated into RNA to sterically hinder 70 RdRp, thereby blocking viral RNA synthesis 21 . Other NAs (favipiravir, ribavirin) are 71 integrated into nascent viral RNA at high rates but are not recognized as endogenous 72 nucleotides in subsequent rounds of replication, increasing the mutation rate and 73 resulting in an inviable genome, a process known as "lethal mutagenesis" [22] [23] [24] The RdRp of SARS-CoV-2 was purified by assembling nsp12, nsp7 and nsp8 (Fig.1a) . 98 Based on previous research, SARS-CoV-2 RdRp polymerase activity was measured 99 by conducting a conventional RNA elongation assay 31 . When NTPs was added, 100 elongation catalyzed by RdRp complex occurred on the RNA duplex, resulting in an 101 intact double-stranded RNA product (Fig.1c) . 102 To test if RdRp uses NDPs or NMPs as a substrate, we performed an RNA extension 103 assay by using NTPs, NDPs or NMPs as substrate, respectively. The result revealed 104 that RdRp synthesized RNA products of the same length regardless of NTPs or NDPs 105 as substrate (Fig.1d) . To examine the template specificity of this RNA synthesis, we 106 challenged 13+23 nt RNA with various NDPs (Fig.1b) . Only the cognate ADP 107 promoted RNA extension, indicating that NDPs incorporation is template-specific 108 (Fig.1e ). synthesized from NDPs has the right sequence (Fig.1f) . Second, the cDNA amplified 118 by 10 cycles of PCR was sequenced by high-throughput sequencing (Fig.1g) . At least 119 50,000 sequences were obtained for each product (SI). The ADP, GDP, CDP and UDP 120 (purchased from Sigma) used in these experiments were characterized by mass 121 spectrometry respectively to make sure these NDPs were not contaminated by NTPs 122 (S1). was used as a template and the elongation of product over time was observed (Fig.2a) . 130 Kinetics curves indicated that the relative incorporation efficiency of NDPs is about 131 7 / 27 two thirds (67.94% ± 2.66%) of that of NTPs (Fig.2b) . These data suggested that the 132 incorporation rate for NDPs is slower than that of NTPs. Subsequently, we decided to 133 test if all four NDPs equally contribute to the slower incorporation rate. A 13+26 nt 134 RNA duplex was synthesized for the assay testing the incorporation efficiency for 135 each NDP (Fig.2c ). Each reaction system contains three NTPs and the NDP of interest 136 (Fig.2d) . Unexpectedly, our data showed that substitution of any single NTP by NDP 137 has no observable effect on the efficiency of RNA synthesis (Fig.2e) . This may imply 138 that the speed of RNA synthesis is only affected by continuous NDP incorporation but 139 not the intermittent insertion. obtained using MTP as the substrate (Fig.3c) . Therefore, it is reasonable to speculate 164 that both MTP and MDP are active forms of monulpiravir in humans. 166 Since both MTP and MDP are active substrates of RdRp we performed an assay to 167 figure out which one is the better substrate. By observing their efficiency in reaction, 168 we found that when the template is G, the relative incorporation efficiency of MTP is in comparison to MTP. MTP and MDP were characterized by HPLC and mass 174 spectrometry to make sure they are the right pure compounds (S2). 175 Next, we tried to determine if MDP is also more efficient in introducing mutations 176 than MTP. The products of RdRp-catalyzed extension reactions containing MTP or 177 MDP using 13+29 nt RNA as a template (Fig. 3e) all the phosphorylation steps and has no risk of incorporation into host mRNA or 236 DNA (Fig.5) . 

Kinetics of Finger Domain Mutants in RB69 DNA Polymerase with Its 456

DNA synthesis from diphosphate substrates by 458 DNA polymerases

Utilization of a 461 deoxynucleoside diphosphate substrate by HIV reverse transcriptase

RNA polymerase transcription, suggesting NDPs may have been 465 substrates for primordial nucleic acid biosynthesis

Structural basis for inhibition of the RNA-dependent RNA 468 polymerase from SARS-CoV-2 by remdesivir

Remdesivir, lopinavir, emetine, and homoharringtonine 471 inhibit SARS-CoV-2 replication in vitro

Clinical benefit of remdesivir in rhesus macaques 474 infected with SARS-CoV-2

A nanoluciferase SARS-CoV-2 for rapid neutralization testing 477 and screening of anti-infective drugs for COVID-19

Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells

Molnupiravir: coding for catastrophe

Dexamethasone: Therapeutic potential, 485 risks, and future projection during COVID-19 pandemic

Virtual screening-driven drug discovery of 488

SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, 489 post-translational modification and host immunity evasion infection 490 mechanisms

RNA-dependent RNA polymerase: Structure, 493 mechanism, and drug discovery for COVID-19

Nucleoside diphosphate and triphosphate prodrugs -An unsolvable 496 task?